Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study (vol 25, pg e1930, 2020)

被引：1
|
作者：
Frass, Michael
Lechleitner, Peter
Gruendling, Christa
Pirker, Claudia
Grasmuk-Siegl, Erwin
Domayer, Julian
Hochmair, Maximilian
Gaertner, Katharina
Duscheck, Cornelia
Muchitsch, Ilse
Marosi, Christine
Schumacher, Michael
Zoechbauer-Mueller, Sabine
Manchanda, Raj K.
Schrott, Andrea
Burghuber, Otto
机构：
来源：
ONCOLOGIST | 2021年 / 26卷 / 03期
关键词：
D O I：
10.1002/onco.13693
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E523 / E523
页数：1
相关论文
共 50 条
  • [41] Top-line results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/iv non-squamous non-small cell lung cancer
    Spigel, D. R.
    Bondarenko, I.
    Losonczy, G.
    Mezger, J.
    Kalofonos, H.
    Reck, M.
    Palmero, R.
    Jang, T.
    Natale, R.
    Sanborn, R. E.
    Lai, J.
    Kallinteris, N.
    Tang, M.
    Shan, J.
    Gerber, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [42] Psychometric evaluation of quality of life measures in a three-arm, randomized, double-blind, placebo-controlled phase III study of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizures (EXIST-3)
    de Vries, Petrus
    Franz, David
    Curatolo, Paolo
    Nabbout, Rima
    Berkowitz, Noah
    Neary, Maureen
    Herbst, Fabian
    Sully, Kate
    Brohan, Elaine
    Lawson, John
    NEUROLOGY, 2017, 88
  • [43] PRELIMINARY SAFETY RESULTS OF MONET-A: A PROSPECTIVE, ASIAN PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL OF THE INVESTIGATIONAL AGENT MOTESANIB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN FOR ASIAN PATIENTS OF ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
    Yoshioka, Hiroshige
    Oshita, Fumihiro
    Nogami, Naoyuki
    Kaneda, Hiroyasu
    Yoh, Kiyotaka
    Kato, Terufumi
    Cho, Byoung Chul
    Chang, Gee-Chen
    Ichinose, Yukito
    Nakagawa, Kazuhiko
    Park, Keunchil
    Yang, James C.
    Achiwa, Hiroyuki
    Asato, Takayuki
    Kubota, Kaoru
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1186 - S1186
  • [44] A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ONARTUZUMAB (METMAB) WITH EITHER BEVACIZUMAB plus PLATINUM plus PACLITAXEL OR PEMETREXED plus PLATINUM AS FIRST-LINE TREATMENT FOR PATIENTS (PTS) WITH STAGE IIIB OR IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Wakelee, H.
    Yu, W.
    Rittweger, K.
    Paton, V. E.
    ANNALS OF ONCOLOGY, 2012, 23 : 445 - 445
  • [45] Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC)
    Vansteenkiste, J.
    Zielinski, M.
    Linder, A.
    Dahabre, J.
    Esteban, E.
    Malinowski, W.
    Jassem, J.
    Passlick, B.
    Lehmann, F.
    Brichard, V. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] BEYOND: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, PHASE III STUDY OF FIRST-LINE CARBOPLATIN/PACLITAXEL (CP) PLUS BEVACIZUMAB (BV) OR PLACEBO (PL) IN CHINESE PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Zhou, Caicun
    Chen, Gongyan
    Liu, Xiaoqing
    Zhu, Yunzhong
    Lu, Shun
    Feng, Jifeng
    He, Jianxing
    Han, Baohui
    Wang, Jie
    Jiang, Guoliang
    Hu, Chunhong
    Zhang, Hao
    Cheng, Gang
    Song, Xiangqun
    Lu, You
    Pan, Hongming
    Zheng, Wenjuan
    Yin, Anny-Yue
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S293 - S293
  • [47] SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer
    Soria, J. -C.
    Fueloep, A.
    Maciel, C.
    Fischer, J. R.
    Girotto, G.
    Lago, S.
    Smit, E.
    Ostoros, G.
    Eberhardt, W. E. E.
    Lishkovska, P.
    Lovick, S.
    Mariani, G.
    McKeown, A.
    Kilgour, E.
    Smith, P.
    Bowen, K.
    Kohlmann, A.
    Carlile, D. J.
    Jaenne, P. A.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 3028 - 3036
  • [48] A phase II multicenter, randomized, placebo controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC).
    Levy, Benjamin Philip
    Giaccone, Giuseppe
    Besse, Benjamin
    Begic, Damir
    Wu, Xiaoling
    Fandi, Abderrahim
    Paz-Ares, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
    Johnson, B.
    Miller, V.
    Amler, L.
    Stern, H.
    Soh, C.
    O'Connor, P.
    Kabbinavar, F.
    EJC SUPPLEMENTS, 2009, 7 (03): : 5 - 6
  • [50] A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
    Miller, V. A.
    Das, A.
    Rossi, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345